Physician profile
Scott E Hendrickson
NPI 1497714687
$7,670.06
in general payments reported to CMS, 2019-2025
49 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $939 · 2021: $675 · 2022: $1,227 · 2023: $1,541 · 2024: $1,204 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,995 · Education: $14.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,994.64 |
| Education | $14.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,716.01 | 2019-2025 | |
| Boston Scientific Corporation | $1,377.78 | 2020-2025 | Exalt Model D, Spyglass, Axios |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $612.14 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Gilead Sciences, INC. | $590.85 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $430.94 | 2019-2024 | Entyvio, Gattex |
| Pfizer INC. | $385.95 | 2022-2025 | |
| Janssen Biotech, INC. | $300.67 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $199.71 | 2019-2025 | |
| Apollo Endosurgery US INC | $155.57 | 2023 | Overstitch Endoscopic Suturing System |
| Regeneron Healthcare Solutions, INC. | $147.72 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $142.38 | 2019-2021 | |
| Cook Medical LLC | $125.26 | 2019 | |
| Janssen Scientific Affairs, LLC | $124.34 | 2019 | |
| Amgen INC. | $94.10 | 2019-2023 | Avsola, Amjevita |
| Bayer Healthcare Pharmaceuticals INC. | $91.03 | 2019-2020 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hendrickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.